Finerenone: Extending MRAs Prognostic Benefit to the Recently Hospitalized and More Symptomatic Patient with HFpEF.

First, while finerenone significantly reduced worsening heart failure events, the reduction in cardiovascular death did not reach statistical significance (HR 0.93).

also in 111,027 other papers

Indeed, patients initiated on finerenone within 7 days of a worsening heart failure event showed a trend toward greater absolute risk reduction compared to stable outpatients (RR 0.74; 95% CI 0.57–0.95), although it did not achieve formal statistical significance ( p for interaction = 0.07) [ 68 ] In TOPCAT, conversely, spironolactone provided less benefit to patients enrolled within a year of an HF hospitalization.

also in 53,322 other papers